Paul Quinlan
2022
In 2022, Paul Quinlan earned a total compensation of $1.1M as General Counsel at Cymabay Therapeutics, a 67% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $210,000 |
|---|---|
| Option Awards | $467,080 |
| Salary | $413,700 |
| Other | $6,020 |
| Total | $1,096,800 |
Quinlan received $467.1K in option awards, accounting for 43% of the total pay in 2022.
Quinlan also received $210K in non-equity incentive plan, $413.7K in salary and $6K in other compensation.
Rankings
In 2022, Paul Quinlan's compensation ranked 2,847th out of 5,753 executives tracked by ExecPay. In other words, Quinlan earned more than 50.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,847 out of 5,753 | 51st |
Division Manufacturing | 1,587 out of 3,133 | 49th |
Major group Chemicals And Allied Products | 735 out of 1,419 | 48th |
Industry group Drugs | 687 out of 1,320 | 48th |
Industry Pharmaceutical Preparations | 496 out of 966 | 49th |
Source: SEC filing on April 19, 2023.
Quinlan's colleagues
We found two more compensation records of executives who worked with Paul Quinlan at Cymabay Therapeutics in 2022.